Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 6/20 | 0.34 |
| ▸ | MMP2 | P08253 | 5/20 | 0.33 |
| ▸ | MMP9 | P14780 | 4/20 | 0.33 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 4/20 | 0.33 |
| ▸ | MMP8 | P22894 | 3/20 | 0.32 |
| ▸ | MMP12 | P39900 | 3/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534370 | 0.88 | MMP13 (0.36) | MMP13ADAMTS4MMP2MMP9MMP1 | |
| SCHEMBL533714 | 0.84 | PTGER2 (0.40) | MMP13ADAMTS4MMP2MMP9MMP1 | |
| SCHEMBL533733 | 0.83 | MMP13 (0.31) | MMP13 | |
| SCHEMBL533734 | 0.81 | PTGER2 (0.47) | — | |
| SCHEMBL13572368 | 0.80 | PTGER2 (0.41) | ADAMTS4PTPN1 | |
| SCHEMBL533315 | 0.79 | PTPRB (0.38) | ADAMTS4PTPRBCTSSCTSK | |
| SCHEMBL532960 | 0.79 | PTGER2 (0.42) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL534320 | 0.78 | PTGER2 (0.38) | ADAMTS4MMP2MMP9PTPRB | |
| SCHEMBL534170 | 0.77 | PTGER2 (0.40) | ADAMTS4MMP2 | |
| SCHEMBL535157 | 0.77 | PTPRB (0.36) | MMP13PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | MMP13 843/4885ADAMTS4 3278/4885MMP2 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.